Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Sae Nishiguchi
Institutions:
Massachusetts General Hospital,
Japanese Foundation For Cancer Research,
The University of Tokyo
Observed institutions:
Massachusetts General Hospital,
Japanese Foundation For Cancer Research,
The University of Tokyo
ORCID:
0009-0002-2356-0409
Observed ORCID:
0009-0002-2356-0409
OpenAlex ID:
A5125042194
176 Bi-paratopic B7-H3-CAR-T cells to treat metastatic triple negative breast cancer
2026
·
Ashlyn T Merce
, Alexander J Armstrong
, et al.
·
Journal for ImmunoTherapy of Cancer
PDF
P-Selectin on activated platelets inhibits the anti-tumor activity of CD8+ T cells through PSGL-1 binding
2026
·
Sae Nishiguchi
, Masaru Yokomura
, et al.
·
Cancer Immunology Immunotherapy
Supplementary Figure S5 from Ibrutinib and PD-1 Blockade Potentiate Mesothelin-Targeting CAR T-cell Therapy in Preclinical Models of Pancreatic Cancer
2026
·
Alexander Armstrong
, Graziella van der Plancke
, et al.
Supplementary Figure S1 from Ibrutinib and PD-1 Blockade Potentiate Mesothelin-Targeting CAR T-cell Therapy in Preclinical Models of Pancreatic Cancer
2026
·
Alexander Armstrong
, Graziella van der Plancke
, et al.
Supplementary Figure S3 from Ibrutinib and PD-1 Blockade Potentiate Mesothelin-Targeting CAR T-cell Therapy in Preclinical Models of Pancreatic Cancer
2026
·
Alexander Armstrong
, Graziella van der Plancke
, et al.
Supplementary Table S3 from Ibrutinib and PD-1 Blockade Potentiate Mesothelin-Targeting CAR T-cell Therapy in Preclinical Models of Pancreatic Cancer
2026
·
Alexander Armstrong
, Graziella van der Plancke
, et al.
Supplementary Figure S4 from Ibrutinib and PD-1 Blockade Potentiate Mesothelin-Targeting CAR T-cell Therapy in Preclinical Models of Pancreatic Cancer
2026
·
Alexander Armstrong
, Graziella van der Plancke
, et al.
Supplementary Table S4 from Ibrutinib and PD-1 Blockade Potentiate Mesothelin-Targeting CAR T-cell Therapy in Preclinical Models of Pancreatic Cancer
2026
·
Alexander Armstrong
, Graziella van der Plancke
, et al.
Supplementary Figure S2 from Ibrutinib and PD-1 Blockade Potentiate Mesothelin-Targeting CAR T-cell Therapy in Preclinical Models of Pancreatic Cancer
2026
·
Alexander Armstrong
, Graziella van der Plancke
, et al.
Supplementary Figure S6 from Ibrutinib and PD-1 Blockade Potentiate Mesothelin-Targeting CAR T-cell Therapy in Preclinical Models of Pancreatic Cancer
2026
·
Alexander Armstrong
, Graziella van der Plancke
, et al.
Supplementary Table S1 from Ibrutinib and PD-1 Blockade Potentiate Mesothelin-Targeting CAR T-cell Therapy in Preclinical Models of Pancreatic Cancer
2026
·
Alexander Armstrong
, Graziella van der Plancke
, et al.
Supplementary Material S1 from Ibrutinib and PD-1 Blockade Potentiate Mesothelin-Targeting CAR T-cell Therapy in Preclinical Models of Pancreatic Cancer
2026
·
Alexander Armstrong
, Graziella van der Plancke
, et al.
Supplementary Table S5 from Ibrutinib and PD-1 Blockade Potentiate Mesothelin-Targeting CAR T-cell Therapy in Preclinical Models of Pancreatic Cancer
2026
·
Alexander Armstrong
, Graziella van der Plancke
, et al.
Supplementary Table S2 from Ibrutinib and PD-1 Blockade Potentiate Mesothelin-Targeting CAR T-cell Therapy in Preclinical Models of Pancreatic Cancer
2026
·
Alexander Armstrong
, Graziella van der Plancke
, et al.
Abstract 6991: Direct adhesion of activated platelets suppresses anti-tumor activity of CTL through CD62p-PSGL1 binding
2026
·
Sae Nishiguchi
, Masaru Yokomura
, et al.
·
Cancer Research
Supplementary Figure S3 from Ibrutinib and PD-1 Blockade Potentiate Mesothelin-Targeting CAR T-cell Therapy in Preclinical Models of Pancreatic Cancer
2026
·
Alexander Armstrong
, Graziella van der Plancke
, et al.
Supplementary Table S2 from Ibrutinib and PD-1 Blockade Potentiate Mesothelin-Targeting CAR T-cell Therapy in Preclinical Models of Pancreatic Cancer
2026
·
Alexander Armstrong
, Graziella van der Plancke
, et al.
Supplementary Table S3 from Ibrutinib and PD-1 Blockade Potentiate Mesothelin-Targeting CAR T-cell Therapy in Preclinical Models of Pancreatic Cancer
2026
·
Alexander Armstrong
, Graziella van der Plancke
, et al.
Supplementary Figure S6 from Ibrutinib and PD-1 Blockade Potentiate Mesothelin-Targeting CAR T-cell Therapy in Preclinical Models of Pancreatic Cancer
2026
·
Alexander Armstrong
, Graziella van der Plancke
, et al.
Data from Ibrutinib and PD-1 Blockade Potentiate Mesothelin-Targeting CAR T-cell Therapy in Preclinical Models of Pancreatic Cancer
2026
·
Alexander Armstrong
, Graziella van der Plancke
, et al.
Supplementary Table S1 from Ibrutinib and PD-1 Blockade Potentiate Mesothelin-Targeting CAR T-cell Therapy in Preclinical Models of Pancreatic Cancer
2026
·
Alexander Armstrong
, Graziella van der Plancke
, et al.
Supplementary Figure S5 from Ibrutinib and PD-1 Blockade Potentiate Mesothelin-Targeting CAR T-cell Therapy in Preclinical Models of Pancreatic Cancer
2026
·
Alexander Armstrong
, Graziella van der Plancke
, et al.
Supplementary Figure S4 from Ibrutinib and PD-1 Blockade Potentiate Mesothelin-Targeting CAR T-cell Therapy in Preclinical Models of Pancreatic Cancer
2026
·
Alexander Armstrong
, Graziella van der Plancke
, et al.
Supplementary Figure S1 from Ibrutinib and PD-1 Blockade Potentiate Mesothelin-Targeting CAR T-cell Therapy in Preclinical Models of Pancreatic Cancer
2026
·
Alexander Armstrong
, Graziella van der Plancke
, et al.
Supplementary Table S5 from Ibrutinib and PD-1 Blockade Potentiate Mesothelin-Targeting CAR T-cell Therapy in Preclinical Models of Pancreatic Cancer
2026
·
Alexander Armstrong
, Graziella van der Plancke
, et al.
Show more works
View as search
Works count:
28
Citation count:
H-index:
I10-index:
Year
Topic
Type